|4Nov 20, 5:35 PM ET

Boston Megan 4

4 · Benitec Biopharma Inc. · Filed Nov 20, 2025

Insider Transaction Report

Form 4
Period: 2025-11-18
Boston Megan
DirectorChief Financial Officer
Transactions
  • Award

    Options (right to buy)

    2025-11-18+200,000200,000 total
    Exercise: $13.53Exp: 2035-11-18Common Stock (200,000 underlying)
Footnotes (1)
  • [F1]The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES